On April 27, 2026, Oruka Therapeutics, Inc. announced successful results from their Phase 2a clinical trial of ORKA-001 for psoriasis, achieving a primary endpoint of 63.5% complete skin clearance compared to 4.8% for placebo, demonstrating strong efficacy and safety.